GM602 / Genervon - LARVOL DELTA

LncRNA Gm16023 ameliorates hyperglycemia-exacerbated septic intestinal injury by modulating macrophage polarization via miR-377-3p/Sirt1 axis. (PubMed, Mol Ther) - "Using both a genetic CD11b-DTR model and clodronate liposome (Cls)-mediated chemical ablation, we demonstrated that macrophage depletion markedly attenuated hyperglycemia-driven septic intestinal injury, underscoring their essential pathogenic role. To facilitate therapeutic delivery, we engineered a lipid nanoparticle (LNP)-encapsulated Gm16023 plasmid system that efficiently delivered lncRNA in vivo and conferred protection against intestinal injury in both in vitro and in vivo models. Collectively, our findings indicate that hyperglycemia promotes macrophage-mediated septic intestinal injury via the lncRNA Gm16023/miR-377-3p/Sirt1 axis, highlighting a potential RNA-based therapeutic strategy for diabetic sepsis."

Journal • Diabetes • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Septic Shock • ITGAM

High-throughput Sequencing Reveals N6-methyladenosine-modified LncRNAs as Potential Biomarkers in Mice with Liver Fibrosis. (PubMed, Curr Gene Ther) - "This study revealed the unique m6A methylation pattern of lncRNAs in LF mice, suggesting that the m6A methylation modification of lncRNAs is related to the occurrence and development of LF."

Journal • Preclinical • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • H19

GAP-PD-Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease (clinicaltrials.gov) - P2a; N=6; Completed; Sponsor: Genervon Biopharmaceuticals, LLC; Recruiting ➔ Completed; Trial primary completion date: Dec 2013 ➔ Jul 2014

Trial completion • Trial primary completion date • Biosimilar • Parkinson's Disease